ArticleBone marrow transplantation2018
Socioeconomic and health system factors associated with lower utilization of hematopoietic cell transplantation in older patients with acute myeloid leukemia.
Article in Bone marrow transplantation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Barriers to Hematopoietic Cell Transplantation for Adults in the United States: A Systematic Review with a Focus on Age.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2020Pooled it
- Access Challenges in Allogeneic Hematopoietic Cell Transplant: Identifying At-Risk US States by Exploring Social Vulnerability, Physician Density, and Unmet Need.JCO oncology practice · 2026Article
- Factors Associated with Receipt of Allogeneic Hematopoietic Cell Transplant and NMDP Donor Search in Older Adults with Acute Myeloid Leukemia.Transplantation and cellular therapy · 2026Article
- Assessing Social Determinants of Health in Transplantation and CAR-T Recipients: Expert Panel Recommendations from the Survivorship Special Interest Group of ASTCT.Transplantation and cellular therapy · 2025Review
- Impact of expanding allogeneic stem cell transplantation on survival in acute myeloid leukemia: a population-based study.Blood cancer journal · 2025Article
- The Caregiver Paradigm in Hematopoietic Cell Transplant: Current and Future Directions.Transplantation and cellular therapy · 2025Review
- Observational
- Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in adults over 70 years old.Blood · 2025Review
- Relationship between age, conditioning intensity, and outcome after allografting in adults age ≥60 years with AML.Bone marrow transplantation · 2025Article
- Utilization of allogeneic hematopoietic stem cell transplantation among patients with newly diagnosed acute myeloid leukemia in California: a population-based linked dataset study.Haematologica · 2025Article
- Access to Transplant Care and Social Determinants of Health.Advances in experimental medicine and biology · 2025Review
- Relationship Between Age, Conditioning Intensity, and Outcome After Allografting in Adults Age ≥60 Years with AML.Research square · 2024Article
- Impact of Race and Ethnicity on Outcomes After Umbilical Cord Blood Transplantation.Transplantation and cellular therapy · 2024Article
- Optimization of older adults by a geriatric assessment-guided multidisciplinary clinic before CAR T-cell therapy.Blood advances · 2024Article
- Hematopoietic Stem-Cell Transplantation: Exploring the Latest Advances and Gaps in Disparities, Psychosocial and Symptom Management Interventions, and Chronic Graft-Versus-Host Disease Care.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2024Review
- Preconditioning Frailty Phenotype Influences Survival and Relapse for Older Allogeneic Transplantation Recipients.Transplantation and cellular therapy · 2024Article
- Racial and Socioeconomic Disparities in Long-Term Outcomes in ≥1 Year Allogeneic Hematopoietic Cell Transplantation Survivors: A CIBMTR Analysis.Transplantation and cellular therapy · 2023Article
- Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation.American journal of hematology · 2023Review
- Analysis of disparities in time to allogeneic transplantation in adults with acute myelogenous leukemia.Blood advances · 2023Article
- Outcomes of Older Adults With AML Treated in Community Versus Academic Centers: An Analysis of Alliance Trials.JCO oncology practice · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Receipt of hematopoietic cell transplantation (HCT) can improve overall survival in older patients with intermediate or high-risk acute myeloid leukemia (AML); however, utilization of HCT is poor. It is important to understand the factors that affect the receipt of HCT in a real-world setting among the older patients. We utilized the National Cancer Database to determine receipt of HCT in older patients (61-75 years) with intermediate or high-risk AML reported between 2003 and 2012. Multivariate logistic regression analysis was used to determine factors associated with receipt of HCT. Only 5.5% of older patients (n = 17,555) underwent HCT. Factors associated with a lower likelihood of receiving HCT included receipt of care in a non-academic hospital, race other than white, older age, Charlson comorbidity score of ≥1, uninsured status, Medicaid or Medicare insurance, and lower educational status. The receipt of HCT in older patients is low and varies based on biological as well as non-biologic factors, such as hospital type, insurance, and educational status. Nationwide efforts to improve access to HCT for appropriate patients are necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.